Some patients with AML and CML exhibited a strong down-regulation and others an up-regulation of DPF3 mRNA levels; however, no clear differences in their clinical-laboratory profiles were observed. This evidence concerns the gene DPF3 and chronic myelogenous leukemia, BCR-ABL1 positive.